|
1
|
Dong G, Zhang S, Shen S, Sun L, Wang X,
Wang H, Wu J, Liu T, Wang C, Wang H, et al: SPATS2, negatively
regulated by miR-145-5p, promotes hepatocellular carcinoma
progression through regulating cell cycle. Cell Death Dis.
11:8372020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang FP, Huang YP, Luo WX, Deng WY, Liu
CQ, Xu LB and Liu C: Construction of a risk score prognosis model
based on hepatocellular carcinoma microenvironment. World J
Gastroenterol. 26:134–153. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang XF, Yang X, Jia HL, Zhu WW, Lu L,
Shi W, Zhang H, Chen JH, Tao YF, Wang ZX, et al: Bcl-2 expression
is a poor predictor for hepatocellular carcinoma prognosis of
andropause-age patients. Cancer Biol Med. 13:459–468. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gnoni A, Santini D, Scartozzi M, Russo A,
Licchetta A, Palmieri V, Lupo L, Faloppi L, Palasciano G, Memeo V,
et al: Hepatocellular carcinoma treatment over sorafenib:
Epigenetics, microRNAs and microenvironment. Is there a light at
the end of the tunnel? Expert Opin Ther Targets. 19:1623–1635.
2015. View Article : Google Scholar
|
|
5
|
Paget S: The distribution of secondary
growth in cancer. Lancet. 1:571–573. 1889. View Article : Google Scholar
|
|
6
|
Sainz B and Heeschen C: Standing out from
the crowd: Cancer stem cells in hepatocellular carcinoma. Cancer
Cell. 23:431–433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J and Zhu Y: Recent advances in liver
cancer stem cells: Non-coding RNAs, oncogenes and oncoproteins.
Front Cell Dev Biol. 8:5483352020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kakinuma T and Hwang ST: Chemokines,
chemokine receptors, and cancer metastasis. J Leukoc Biol.
79:639–651. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nagarsheth N, Wicha MS and Zou W:
Chemokines in the cancer microenvironment and their relevance in
cancer immunotherapy. Nat Rev Immunol. 17:559–572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Griffith JW, Sokol CL and Luster AD:
Chemokines and chemokine receptors: Positioning cells for host
defense and immunity. Annu Rev Immunol. 32:659–702. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sakai N, Yoshidome H, Shida T, Kimura F,
Shimizu H, Ohtsuka M, Takeuchi D, Sakakibara M and Miyazaki M:
CXCR4/CXCL12 expression profile is associated with tumor
microenvironment and clinical outcome of liver metastases of
colorectal cancer. Clin Exp Metastasis. 29:101–110. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rezaeeyan H, Shirzad R, McKee TD and Saki
N: Role of chemokines in metastatic niche: New insights along with
a diagnostic and prognostic approach. APMIS. 126:359–370. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Raffaella B and Graham GJ: Atypical
chemokine receptors and their roles in the resolution of the
inflammatory response. Front Immunol. 7:2242016.PubMed/NCBI
|
|
14
|
Saaber F, Schütz D, Miess E, Abe P,
Desikan S, Ashok Kumar P, Balk S, Huang K, Beaulieu JM, Schulz S
and Stumm R: ACKR3 regulation of neuronal migration requires ACKR3
phosphorylation, but not β-Arrestin. Cell Rep. 26:1473–1488.e9.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Purvanov V, Matti C, Samson GPB, Kindinger
I and Legler DF: Fluorescently tagged CCL19 and CCL21 to monitor
CCR7 and ACKR4 functions. Int J Mol Sci. 19:38762018. View Article : Google Scholar
|
|
16
|
Matti C, D'Uonnolo G, Artinger M, Melgrati
S, Salnikov A, Thelen S, Purvanov V, Strobel TD, Spannagel L,
Thelen M and Legler DF: CCL20 is a novel ligand for the scavenging
atypical chemokine receptor 4. J Leukoc Biol. 107:1137–1154. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Do HTT, Lee CH and Cho J: Chemokines and
their receptors: Multifaceted roles in cancer progression and
potential value as cancer prognostic markers. Cancers (Basel).
12:2872020. View Article : Google Scholar
|
|
18
|
Ozakyol A: Global epidemiology of
hepatocellular carcinoma (HCC Epidemiology). J Gastrointest Cancer.
48:238–240. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Giannelli G, Rani B, Dituri F, Cao Y and
Palasciano G: Moving towards personalised therapy in patients with
hepatocellular carcinoma: The role of the microenvironment. Gut.
63:1668–1676. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marra F and Tacke F: Roles for chemokines
in liver disease. Gastroenterology. 147:577–594.e1. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chiu DK, Xu IM, Lai RK, Tse AP, Wei LL,
Koh HY, Li LL, Lee D, Lo RC, Wong CM, et al: Hypoxia induces
myeloid-derived suppressor cell recruitment to hepatocellular
carcinoma through chemokine (C-C motif) ligand 26. Hepatology.
64:797–813. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kryczek I, Wang L, Wu K, Li W, Zhao E, Cui
T, Wei S, Liu Y, Wang Y, Vatan L, et al: Inflammatory regulatory T
cells in the microenvironments of ulcerative colitis and colon
carcinoma. Oncoimmunology. 5:e11054302016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kryczek I, Wu K, Zhao E, Wei S, Vatan L,
Szeliga W, Huang E, Greenson J, Chang A, Roliński J, et al:
IL-17+ regulatory T cells in the microenvironments of
chronic inflammation and cancer. J Immunol. 186:4388–4395. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han KQ, He XQ, Ma MY, Guo XD, Zhang XM,
Chen J, Han H, Zhang WW, Zhu QG, Nian H and Ma LJ: Inflammatory
microenvironment and expression of chemokines in hepatocellular
carcinoma. World J Gastroenterol. 21:4864–4874. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dagouassat M, Suffee N, Hlawaty H, Haddad
O, Charni F, Laguillier C, Vassy R, Martin L, Schischmanoff PO,
Gattegno L, et al: Monocyte chemoattractant protein-1 (MCP-1)/CCL2
secreted by hepatic myofibroblasts promotes migration and invasion
of human hepatoma cells. Int J Cancer. 126:1095–1108.
2010.PubMed/NCBI
|
|
26
|
Zhang H, He G, Kong Y, Chen Y, Wang B, Sun
X, Jia B, Xie X, Wang X, Chen D, et al: Tumour-activated liver
stromal cells regulate myeloid-derived suppressor cells
accumulation in the liver. Clin Exp Immunol. 188:96–108. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kee JY, Ito A, Hojo S, Hashimoto I,
Igarashi Y, Tsukada K, Irimura T, Shibahara N, Nakayama T, Yoshie
O, et al: Chemokine CXCL16 suppresses liver metastasis of
colorectal cancer via augmentation of tumor-infiltrating natural
killer T cells in a murine model. Oncol Rep. 29:975–982. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kee JY, Ito A, Hojo S, Hashimoto I,
Igarashi Y, Tsuneyama K, Tsukada K, Irimura T, Shibahara N,
Takasaki I, et al: CXCL16 suppresses liver metastasis of colorectal
cancer by promoting TNF-α-induced apoptosis by tumor-associated
macrophages. BMC Cancer. 14:9492014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Adamski V, Hattermann K, Kubelt C, Cohrs
G, Lucius R, Synowitz M, Sebens S and Held-Feindt J: Entry and exit
of chemotherapeutically-promoted cellular dormancy in glioblastoma
cells is differentially affected by the chemokines CXCL12, CXCL16,
and CX3CL1. Oncogene. 39:4421–4435. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Takiguchi G, Nishita M, Kurita K, Kakeji Y
and Minami Y: Wnt5a-Ror2 signaling in mesenchymal stem cells
promotes proliferation of gastric cancer cells by activating
CXCL16-CXCR6 axis. Cancer Sci. 107:290–297. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shi JY, Yang LX, Wang ZC, Wang LY, Zhou J,
Wang XY, Shi GM, Ding ZB, Ke AW, Dai Z, et al: CC chemokine
receptor-like 1 functions as a tumour suppressor by impairing
CCR7-related chemotaxis in hepatocellular carcinoma. J Pathol.
235:546–558. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shi JY, Duan M, Sun QM, Yang L, Wang ZC,
Mynbaev OA, He YF, Wang LY, Zhou J, Tang QQ, et al: Naive Treg-like
CCR7+ mononuclear cells indicate unfavorable prognosis
in hepatocellular carcinoma. Tumour Biol. 37:9909–9917. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wong HS, Jaumouillé V, Heit B, Doodnauth
SA, Patel S, Huang YW, Grinstein S and Robinson LA: Cytoskeletal
confinement of CX3CL1 limits its susceptibility to proteolytic
cleavage by ADAM10. Mol Biol Cell. 25:3884–3899. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun C, Hu A, Wang S, Tian B, Jiang L,
Liang Y, Wang H and Dong J: ADAM17-regulated CX3CL1 expression
produced by bone marrow endothelial cells promotes spinal
metastasis from hepatocellular carcinoma. Int J Oncol. 57:249–263.
2020.PubMed/NCBI
|
|
35
|
Liu W, Jiang L, Bian C, Liang Y, Xing R,
Yishakea M and Dong J: Role of CX3CL1 in diseases. Arch Immunol
Ther Exp (Warsz). 64:371–383. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu P, Liang Y, Jiang L, Wang H, Wang S
and Dong J: CX3CL1/fractalkine enhances prostate cancer spinal
metastasis by activating the Src/FAK pathway. Int J Oncol.
53:1544–1556. 2018.PubMed/NCBI
|
|
37
|
Liang Y, Yi L, Liu P, Jiang L, Wang H, Hu
A, Sun C and Dong J: CX3CL1 involves in breast cancer metastasizing
to the spine via the Src/FAK signaling pathway. J Cancer.
9:3603–3612. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zheng J, Yang M, Shao J, Miao Y, Han J and
Du J: Chemokine receptor CX3CR1 contributes to macrophage survival
in tumor metastasis. Mol Cancer. 12:1412013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen EB, Zhou ZJ, Xiao K, Zhu GQ, Yang Y,
Wang B, Zhou SL, Chen Q, Yin D, Wang Z, et al: The
miR-561-5p/CX3CL1 signaling axis regulates pulmonary
metastasis in hepatocellular carcinoma involving
CX3CR1+ natural killer cells infiltration.
Theranostics. 9:4779–4794. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Miao S, Lu M, Liu Y, Shu D, Zhu Y, Song W,
Ma Y, Ma R, Zhang B, Fang C and Ming ZY: Platelets are recruited to
hepatocellular carcinoma tissues in a CX3CL1-CX3CR1 dependent
manner and induce tumour cell apoptosis. Mol Oncol. 14:2546–2559.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yoshida T, Imai T, Takagi S, Nishimura M,
Ishikawa I, Yaoi T and Yoshie O: Structure and expression of two
highly related genes encoding SCM-1/human lymphotactin. FEBS Lett.
395:82–88. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lei Y and Takahama Y: XCL1 and XCR1 in the
immune system. Microbes Infect. 14:262–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yamazaki C, Sugiyama M, Ohta T, Hemmi H,
Hamada E, Sasaki I, Fukuda Y, Yano T, Nobuoka M, Hirashima T, et
al: Critical roles of a dendritic cell subset expressing a
chemokine receptor, XCR1. J Immunol. 190:6071–6082. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Khurram SA, Whawell SA, Bingle L, Murdoch
C, McCabe BM and Farthing PM: Functional expression of the
chemokine receptor XCR1 on oral epithelial cells. J Pathol.
221:153–163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gantsev SK, Umezawa K, Islamgulov DV,
Khusnutdinova EK, Ishmuratova RS, Frolova VY and Kzyrgalin SR: The
role of inflammatory chemokines in lymphoid neoorganogenesis in
breast cancer. Biomed Pharmacother. 67:363–366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim M, Rooper L, Xie J, Rayahin J,
Burdette JE, Kajdacsy-Balla AA and Barbolina MV: The lymphotactin
receptor is expressed in epithelial ovarian carcinoma and
contributes to cell migration and proliferation. Mol Cancer Res.
10:1419–1429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang T, Han S, Wu Z, Han Z, Yan W, Liu T,
Wei H, Song D, Zhou W, Yang X and Xiao J: XCR1 promotes cell growth
and migration and is correlated with bone metastasis in non-small
cell lung cancer. Biochem Biophys Res Commun. 464:635–641. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yanru W, Zhenyu B, Zhengchuan N, Qi Q,
Chunmin L and Weiqiang Y: Transcriptomic analyses of chemokines
reveal that down-regulation of XCR1 is associated with advanced
hepatocellular carcinoma. Biochem Biophys Res Commun.
496:1314–1321. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li X: The inducers of immunogenic cell
death for tumor immunotherapy. Tumori. 104:1–8. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mizumoto Y, Hemmi H, Katsuda M, Miyazawa
M, Kitahata Y, Miyamoto A, Nakamori M, Ojima T, Matsuda K, Nakamura
M, et al: Anticancer effects of chemokine-directed antigen delivery
to a cross-presenting dendritic cell subset with immune checkpoint
blockade. Br J Cancer. 122:1185–1193. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Spranger S and Gajewski TF: A new paradigm
for tumor immune escape: β-catenin-driven immune exclusion. J
Immunother Cancer. 3:432015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Botelho NK, Tschumi BO, Hubbell JA, Swartz
MA, Donda A and Romero P: Combination of synthetic long peptides
and XCL1 fusion proteins results in superior tumor control. Front
Immunol. 10:2942019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chen K, Wu Z, Zhao H, Wang Y, Ge Y, Wang
D, Li Z, An C, Liu Y, Wang F, et al: XCL1/Glypican-3 fusion gene
immunization generates potent antitumor cellular immunity and
enhances Anti-PD-1 efficacy. Cancer Immunol Res. 8:81–93. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Audsley KM, McDonnell AM and Waithman J:
Cross-presenting XCR1+ dendritic cells as targets for
cancer immunotherapy. Cells. 9:5652020. View Article : Google Scholar
|
|
55
|
Wylie B, Read J, Buzzai AC, Wagner T, Troy
N, Syn G, Stone SR, Foley B, Bosco A, Cruickshank MN, et al:
CD8+XCR1neg dendritic cells express high
levels of toll-like receptor 5 and a unique complement of endocytic
receptors. Front Immunol. 9:29902019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Qin CJ, Zhao LH, Zhou X, Zhang HL, Wen W,
Tang L, Zeng M, Wang MD, Fu GB, Huang S, et al: Inhibition of
dipeptidyl peptidase IV prevents high fat diet-induced liver cancer
angiogenesis by downregulating chemokine ligand 2. Cancer Lett.
420:26–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Giles AJ, Reid CM, Evans JD, Murgai M,
Vicioso Y, Highfill SL, Kasai M, Vahdat L, Mackall CL, Lyden D, et
al: Activation of hematopoietic stem/progenitor cells promotes
immunosuppression within the pre-metastatic niche. Cancer Res.
76:1335–1347. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chang AL, Miska J, Wainwright DA, Dey M,
Rivetta CV, Yu D, Kanojia D, Pituch KC, Qiao J, Pytel P, et al:
CCL2 produced by the glioma microenvironment is essential for the
recruitment of regulatory T cells and myeloid-derived suppressor
cells. Cancer Res. 76:5671–5682. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Qi S, Perrino S, Miao X, Lamarche-Vane N
and Brodt P: The chemokine CCL7 regulates invadopodia maturation
and MMP-9 mediated collagen degradation in liver-metastatic
carcinoma cells. Cancer Lett. 483:98–113. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wu Q, Chen JX, Chen Y, Cai LL, Wang XZ,
Guo WH and Zheng JF: The chemokine receptor CCR10 promotes
inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway
activation. Cell Death Dis. 9:2322018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hippe A, Braun SA, Oláh P, Gerber PA,
Schorr A, Seeliger S, Holtz S, Jannasch K, Pivarcsi A, Buhren B, et
al: EGFR/Ras-induced CCL20 production modulates the tumour
microenvironment. Br J Cancer. 123:942–954. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Du D, Liu Y, Qian H, Zhang B, Tang X,
Zhang T and Liu W: The effects of the CCR6/CCL20 biological axis on
the invasion and metastasis of hepatocellular carcinoma. Int J Mol
Sci. 15:6441–6452. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Huang F and Geng XP: Chemokines and
hepatocellular carcinoma. World J Gastroenterol. 16:1832–1836.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tan H, Wang S and Zhao L: A
tumour-promoting role of Th9 cells in hepatocellular carcinoma
through CCL20 and STAT3 pathways. Clin Exp Pharmacol Physiol.
44:213–221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Facciabene A, Peng X, Hagemann IS, Balint
K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L and
Coukos G: Tumour hypoxia promotes tolerance and angiogenesis via
CCL28 and T(reg) cells. Nature. 475:226–230. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gao Y, Zhou Z, Lu S, Huang X, Zhang C,
Jiang R, Yao A, Sun B and Wang X: Chemokine CCL15 mediates
migration of human bone marrow-derived mesenchymal stem cells
toward hepatocellular carcinoma. Stem Cells. 34:1112–1122. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Singh SK, Mishra MK, Eltoum IA, Bae S,
Lillard JW Jr and Singh R: CCR5/CCL5 axis interaction promotes
migratory and invasiveness of pancreatic cancer cells. Sci Rep.
8:13232018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Singh SK, Mishra MK, Rivers BM, Gordetsky
JB, Bae S and Singh R: Biological and clinical significance of the
CCR5/CCL5 axis in hepatocellular carcinoma. Cancers (Basel).
12:8832020. View Article : Google Scholar
|
|
69
|
Sasaki R, Devhare PB, Steele R, Ray R and
Ray RB: Hepatitis C virus-induced CCL5 secretion from macrophages
activates hepatic stellate cells. Hepatology. 66:746–757. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
González-Martín A, Mira E and Mañes S:
CCR5 in cancer immunotherapy: More than an ‘attractive’ receptor
for T cells. Oncoimmunology. 1:106–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wang T, Zhan Q, Peng X, Qiu Z and Zhao T:
CCL2 influences the sensitivity of lung cancer A549 cells to
docetaxel. Oncol Lett. 16:1267–1274. 2018.PubMed/NCBI
|
|
72
|
Pasquier J, Gosset M, Geyl C,
Hoarau-Véchot J, Chevrot A, Pocard M, Mirshahi M, Lis R, Rafii A
and Touboul C: CCL2/CCL5 secreted by the stroma induce IL-6/PYK2
dependent chemoresistance in ovarian cancer. Mol Cancer. 17:472018.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Su S, Sun X, Zhang Q, Zhang Z and Chen J:
CCL20 promotes ovarian cancer chemotherapy resistance by regulating
ABCB1 expression. Cell Struct Funct. 44:21–28. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Vaquero J, Briz O, Herraez E, Muntané J
and Marin JJ: Activation of the nuclear receptor FXR enhances
hepatocyte chemoprotection and liver tumor chemoresistance against
genotoxic compounds. Biochim Biophys Acta. 1833:2212–2219. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Gu Y, Li X, Bi Y, Zheng Y, Wang J, Li X,
Huang Z, Chen L and Huang Y and Huang Y: CCL14 is a prognostic
biomarker and correlates with immune infiltrates in hepatocellular
carcinoma. Aging (Albany NY). 12:784–807. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Rodríguez-Perea AL, Rojas M and
Velilla-Hernández PA: High concentrations of atorvastatin reduce
in-vitro function of conventional T and regulatory T cells. Clin
Exp Immunol. 196:237–248. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhu M, Xu W, Wei C, Huang J, Xu J, Zhang
Y, Zhao Y, Chen J, Dong S, Liu B and Liang C: CCL14 serves as a
novel prognostic factor and tumor suppressor of HCC by modulating
cell cycle and promoting apoptosis. Cell Death Dis. 10:7962019.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhang X, Wan JX, Ke ZP, Wang F, Chai HX
and Liu JQ: TMEM88, CCL14 and CLEC3B as prognostic biomarkers for
prognosis and palindromia of human hepatocellular carcinoma. Tumour
Biol. 39:10104283177089002017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wilson GC, Kuboki S, Freeman CM, Nojima H,
Schuster RM, Edwards MJ and Lentsch AB: CXC chemokines function as
a rheostat for hepatocyte proliferation and liver regeneration.
PLoS One. 10:e01200922015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Vandercappellen J, Van Damme J and Struyf
S: The role of CXC chemokines and their receptors in cancer. Cancer
Lett. 267:226–244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Liu G, Yang ZF, Zhou PY, Zhou C, Guan RY,
Sun BY, Fan J, Zhou J, Yi Y and Qiu SJ: ROR-α-1 inhibits the
proliferation, invasion, and migration of hepatocellular carcinoma
MHCC97H via downregulation of chemokine CXCL5. Cytokine.
129:1550042020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW,
Wang Z, Fan J, Dai Z and Zhou J: CXCR2/CXCL5 axis contributes to
epithelial-mesenchymal transition of HCC cells through activating
PI3K/Akt/GSK-3β/Snail signaling. Cancer Lettr. 358:124–135. 2015.
View Article : Google Scholar
|
|
83
|
Li XP, Yang XY, Biskup E, Zhou J, Li HL,
Wu YF, Chen ML and Xu F: Co-expression of CXCL8 and HIF-1α is
associated with metastasis and poor prognosis in hepatocellular
carcinoma. Oncotarget. 6:22880–22889. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Yamamoto M, Kikuchi H, Ohta M, Kawabata T,
Hiramatsu Y, Kondo K, Baba M, Kamiya K, Tanaka T, Kitagawa M and
Konno H: TSU68 prevents liver metastasis of colon cancer xenografts
by modulating the premetastatic niche. Cancer Res. 68:9754–9762.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Van den Eynden GG, Majeed AW, Illemann M,
Vermeulen PB, Bird NC, Høyer-Hansen G, Eefsen RL, Reynolds AR and
Brodt P: The multifaceted role of the microenvironment in liver
metastasis: Biology and clinical implications. Cancer Res.
73:2031–2043. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Li L, Zhu YH, Li Y and Guan XY:
Identification of chemokine CXCL10 in tumor microenvironment by
antibody array as a prognostic marker in hepatocellular carcinoma.
Neoplasma. 64:778–786. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Li B, Su H, Cao J and Zhang L: CXCL13
rather than IL-31 is a potential indicator in patients with
hepatocellular carcinoma. Cytokine. 89:91–97. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Song X, Wang Z, Jin Y, Wang Y and Duan W:
Loss of miR-532-5p in vitro promotes cell proliferation and
metastasis by influencing CXCL2 expression in HCC. Am J Transl Res.
7:2254–2261. 2015.PubMed/NCBI
|
|
89
|
Ding J, Xu K, Zhang J, Lin B, Wang Y, Yin
S, Xie H, Zhou L and Zheng S: Overexpression of CXCL2 inhibits cell
proliferation and promotes apoptosis in hepatocellular carcinoma.
BMB Rep. 51:630–635. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Subat S, Mogushi K, Yasen M, Kohda T,
Ishikawa Y and Tanaka H: Identification of genes and pathways,
including the CXCL2 axis, altered by DNA methylation in
hepatocellular carcinoma. J Cancer Res Clin Oncol. 145:675–684.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Shi A, Shi H, Dong L, Xu S, Jia M, Guo X
and Wang T: CXCR7 as a chemokine receptor for SDF-1 promotes
gastric cancer progression via MAPK pathways. Scand J
Gastroenterol. 52:745–753. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Li D, Qu C, Ning Z, Wang H, Zang K, Zhuang
L, Chen L, Wang P and Meng Z: Radiation promotes
epithelial-to-mesenchymal transition and invasion of pancreatic
cancer cell by activating carcinoma-associated fibroblasts. Am J
Cancer Res. 6:2192–2206. 2016.PubMed/NCBI
|
|
93
|
Croker AK and Allan AL: Cancer stem cells:
Implications for the progression and treatment of metastatic
disease. J Cell Mol Med. 12:374–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Jahanban-Esfahlan R, de la Guardia M,
Ahmadi D and Yousefi B: Modulating tumor hypoxia by nanomedicine
for effective cancer therapy. J Cell Physiol. 233:2019–2031. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Teng F, Tian WY, Wang YM, Zhang YF, Guo F,
Zhao J, Gao C and Xue FX: Cancer-associated fibroblasts promote the
progression of endometrial cancer via the SDF-1/CXCR4 axis. J
Hematol Oncol. 9:82016. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wang C, Wang MD, Cheng P, Huang H, Dong W,
Zhang WW, Li PP, Lin C, Pan ZY, Wu MC and Zhou WP: Hepatitis B
virus X protein promotes the stem-like properties of
OV6+ cancer cells in hepatocellular carcinoma. Cell
Death Dis. 8:e25602017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Kaemmerer D, Schindler R, Mußbach F,
Dahmen U, Altendorf-Hofmann A, Dirsch O, Sänger J, Schulz S and
Lupp A: Somatostatin and CXCR4 chemokine receptor expression in
hepatocellular and cholangiocellular carcinomas: Tumor capillaries
as promising targets. BMC Cancer. 17:8962017. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Li H, Yang W, Chen PW, Alizadeh H and
Niederkorn JY: Inhibition of chemokine receptor expression on uveal
melanomas by CXCR4 siRNA and its effect on uveal melanoma liver
metastases. Invest Ophthalmol Vis Sci. 50:5522–5528. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Deol A, Abrams J, Masood A, Al-Kadhimi Z,
Abidi MH, Ayash L, Lum LG, Ratanatharathorn V and Uberti JP:
Long-term follow up of patients proceeding to transplant using
plerixafor mobilized stem cells and incidence of secondary
myelodysplastic syndrome/AML. Bone Marrow Transplant. 48:1112–1116.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Collins PJ, McCully ML, Martínez-Muñoz L,
Santiago C, Wheeldon J, Caucheteux S, Thelen S, Cecchinato V,
Laufer JM, Purvanov V, et al: Epithelial chemokine CXCL14
synergizes with CXCL12 via allosteric modulation of CXCR4. FASEB J.
31:3084–3097. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Chen Y, Teng F, Wang G and Nie Z:
Overexpression of CXCR7 induces angiogenic capacity of human
hepatocellular carcinoma cells via the AKT signaling pathway. Oncol
Rep. 36:2275–2281. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Lin L, Han MM, Wang F, Xu LL, Yu HX and
Yang PY: CXCR7 stimulates MAPK signaling to regulate hepatocellular
carcinoma progression. Cell Death Dis. 5:e14882014. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Billottet C, Quemener C and Bikfalvi A:
CXCR3, a double-edged sword in tumor progression and angiogenesis.
Biochim Biophys Acta. 1836:287–295. 2013.PubMed/NCBI
|
|
104
|
Ma B, Khazali A and Wells A: CXCR3 in
carcinoma progression. Histol Histopathol. 30:781–792.
2015.PubMed/NCBI
|
|
105
|
Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH,
Sun J, Yi Y, Shi JY, Shi GM, Ding ZB, et al: CXCR6 upregulation
contributes to a proinflammatory tumor microenvironment that drives
metastasis and poor patient outcomes in hepatocellular carcinoma.
Cancer Res. 72:3546–3556. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wu Y, Tian L, Xu Y, Zhang M, Xiang S, Zhao
J and Wang Z: CXCR7 silencing inhibits the migration and invasion
of human tumor endothelial cells derived from hepatocellular
carcinoma by suppressing STAT3. Mol Med Rep. 18:1644–1650.
2018.PubMed/NCBI
|
|
107
|
Xu Y, Fang F, Jiao H, Zheng X, Huang L, Yi
X and Zhao W: Activated hepatic stellate cells regulate MDSC
migration through the SDF-1/CXCR4 axis in an orthotopic mouse model
of hepatocellular carcinoma. Cancer Immunol Immunother.
68:1959–1969. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Tian H, Huang P, Zhao Z, Tang W and Xia J:
HIF-1α plays a role in the chemotactic migration of hepatocarcinoma
cells through the modulation of CXCL6 expression. Cell Physiol
Biochem. 34:1536–1546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Shen H, Yao X, Li H, Li X, Zhang T, Sun Q,
Ji C and Chen G: Role of exosomes derived from miR-133b modified
MSCs in an experimental rat model of intracerebral hemorrhage. J
Mol Neurosci. 64:421–430. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Halvaei S, Daryani S, Eslami-S Z, Samadi
T, Jafarbeik-Iravani N, Bakhshayesh TO, Majidzadeh-A K and Esmaeili
R: Exosomes in cancer liquid biopsy: A focus on breast cancer. Mol
Ther Nucleic Acids. 10:131–141. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Anel A, Gallego-Lleyda A, de Miguel D,
Naval J and Martínez-Lostao L: Role of exosomes in the regulation
of T-cell mediated immune responses and in autoimmune disease.
Cells. 8:1542019. View Article : Google Scholar
|
|
112
|
Almeida VH, Rondon AMR, Gomes T and
Monteiro RQ: Novel aspects of extracellular vesicles as mediators
of cancer-associated thrombosis. Cells. 8:7162019. View Article : Google Scholar
|
|
113
|
Rao PSS, O'Connell K and Finnerty TK:
Potential role of extracellular vesicles in the pathophysiology of
drug addiction. Mol Neurobiol. 55:6906–6913. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Kohama I, Kosaka N, Chikuda H and Ochiya
T: An insight into the roles of MicroRNAs and exosomes in sarcoma.
Cancers (Basel). 11:4282019. View Article : Google Scholar
|
|
115
|
Mashouri L, Yousefi H, Aref AR, Ahadi AM,
Molaei F and Alahari SK: Exosomes: Composition, biogenesis, and
mechanisms in cancer metastasis and drug resistance. Mol Cancer.
18:752019. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Sun JF, Zhang D, Gao CJ, Zhang YW and Dai
QS: Exosome-mediated MiR-155 transfer contributes to hepatocellular
carcinoma cell proliferation by targeting PTEN. Med Sci Monit Basic
Res. 25:218–228. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Lee JY and Kim HS: Extracellular vesicles
in neurodegenerative diseases: A double-edged sword. Tissue Eng
Regen Med. 14:667–678. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Johnsen KB, Gudbergsson JM, Skov MN,
Pilgaard L, Moos T and Duroux M: A comprehensive overview of
exosomes as drug delivery vehicles-endogenous nanocarriers for
targeted cancer therapy. Biochim Biophys Acta. 1846:75–87.
2014.PubMed/NCBI
|
|
119
|
Yi YW, Lee JH, Kim SY, Pack CG, Ha DH,
Park SR, Youn J and Cho BS: Advances in analysis of biodistribution
of exosomes by molecular imaging. Int J Mol Sci. 21:6652020.
View Article : Google Scholar
|
|
120
|
Wu P, Zhang B, Ocansey DKW, Xu W and Qian
H: Extracellular vesicles: A bright star of nanomedicine.
Biomaterials. 6:1204672020. View Article : Google Scholar
|
|
121
|
Kim MS, Haney MJ, Zhao Y, Mahajan V,
Deygen I, Klyachko NL, Inskoe E, Piroyan A, Sokolsky M, Okolie O,
et al: Development of exosome-encapsulated paclitaxel to overcome
MDR in cancer cells. Nanomedicine. 12:655–664. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Si Y, Kim S, Zhang E, Tang Y,
Jaskula-Sztul R, Markert JM, Chen H, Zhou L and Liu XM: Targeted
exosomes for drug delivery: Biomanufacturing, surface tagging, and
validation. Biotechnol J. 15:e19001632020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Prada I and Meldolesi J: Binding and
fusion of extracellular vesicles to the plasma membrane of their
cell targets. Int J Mol Sci. 17:12962016. View Article : Google Scholar
|
|
124
|
Nakase I and Futaki S: Combined treatment
with a pH-sensitive fusogenic peptide and cationic lipids achieves
enhanced cytosolic delivery of exosomes. Sci Rep. 5:101122015.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Kooijmans SA, Aleza CG, Roffler SR, van
Solinge WW, Vader P and Schiffelers RM: Display of GPI-anchored
anti-EGFR nanobodies on extracellular vesicles promotes tumour cell
targeting. J Extracell Vesicles. 5:310532016. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Hashimoto K, Ochi H, Sunamura S, Kosaka N,
Mabuchi Y, Fukuda T, Yao K, Kanda H, Ae K, Okawa A, et al:
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in
the bone metastatic microenvironment via targeting ARHGAP1 and
FAM134A. Proc Natl Acad Sci USA. 115:2204–2209. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Luis-Ravelo D, Antón I, Zandueta C,
Valencia K, Ormazábal C, Martínez-Canarias S, Guruceaga E, Perurena
N, Vicent S, De Las Rivas J and Lecanda F: A gene signature of bone
metastatic colonization sensitizes for tumor-induced osteolysis and
predicts survival in lung cancer. Oncogene. 33:5090–5099. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Hoshino A, Costa-Silva B, Shen TL,
Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di
Giannatale A, Ceder S, et al: Tumour exosome integrins determine
organotropic metastasis. Nature. 527:329–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Li H, Yang C, Shi Y and Zhao L: Exosomes
derived from siRNA against GRP78 modified bone-marrow-derived
mesenchymal stem cells suppress Sorafenib resistance in
hepatocellular carcinoma. J Nanobiotechnology. 16:1032018.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Viñas JL, Spence M, Gutsol A, Knoll W,
Burger D, Zimpelmann J, Allan DS and Burns KD: Receptor-ligand
interaction mediates targeting of endothelial colony forming
cell-derived exosomes to the kidney after ischemic injury. Sci Rep.
8:163202018. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Ciullo A, Biemmi V, Milano G, Bolis S,
Cervio E, Fertig ET, Gherghiceanu M, Moccetti T, Camici GG,
Vassalli G and Barile L: Exosomal expression of CXCR4 targets
cardioprotective vesicles to myocardial infarction and improves
outcome after systemic administration. Int J Mol Sci. 20:4682019.
View Article : Google Scholar
|
|
132
|
Wei G, Jie Y, Haibo L, Chaoneng W, Dong H,
Jianbing Z, Junjie G, Leilei M, Hongtao S, Yunzeng Z and Junbo G:
Dendritic cells derived exosomes migration to spleen and induction
of inflammation are regulated by CCR7. Sci Rep. 7:429962017.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Longo V, Gnoni A, Casadei Gardini A,
Pisconti S, Licchetta A, Scartozzi M, Memeo R, Palmieri VO, Aprile
G, Santini D, et al: Immunotherapeutic approaches for
hepatocellular carcinoma. Oncotarget. 8:33897–33910. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Liu YC, Yeh CT and Lin KH: Cancer stem
cell functions in hepatocellular carcinoma and comprehensive
therapeutic strategies. Cells. 9:13312020. View Article : Google Scholar
|
|
135
|
Liu LZ, Zhang Z, Zheng BH, Shi Y, Duan M,
Ma LJ, Wang ZC, Dong LQ, Dong PP, Shi JY, et al: CCL15 recruits
suppressive monocytes to facilitate Immune escape and disease
progression in hepatocellular carcinoma. Hepatology. 69:143–159.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Sun F, Wang J, Sun Q, Li F, Gao H, Xu L,
Zhang J, Sun X, Tian Y, Zhao Q, et al: Interleukin-8 promotes
integrin β3 upregulation and cell invasion through PI3K/Akt pathway
in hepatocellular carcinoma. J Exp Clin Cancer Res. 38:4492019.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Li L, Xu L, Yan J, Zhen ZJ, Ji Y, Liu CQ,
Lau WY, Zheng L and Xu J: CXCR2-CXCL1 axis is correlated with
neutrophil infiltration and predicts a poor prognosis in
hepatocellular carcinoma. J Exp Clin Cancer Res. 34:1292015.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Lu Y, Li S, Ma L, Li Y, Zhang X, Peng Q,
Mo C, Huang L, Qin X and Liu Y: Type conversion of secretomes in a
3D TAM2 and HCC cell co-culture system and functional importance of
CXCL2 in HCC. Sci Rep. 6:245582016. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Zhang L, Zhang L, Li H, Ge C, Zhao F, Tian
H, Chen T, Jiang G, Xie H, Cui Y, et al: CXCL3 contributes to
CD133+ CSCs maintenance and forms a positive feedback
regulation loop with CD133 in HCC via Erk1/2 phosphorylation. Sci
Rep. 6:274262016. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH,
Wang Z, Huang XW, Fan J and Zhou J: Overexpression of CXCL5
mediates neutrophil infiltration and indicates poor prognosis for
hepatocellular carcinoma. Hepatology. 56:2242–2254. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Ding Q, Xia Y, Ding S, Lu P, Sun L and Liu
M: An alternatively spliced variant of CXCR3 mediates the
metastasis of CD133+ liver cancer cells induced by CXCL9.
Oncotarget. 7:14405–14414. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Ouyang Y, Liu K, Hao M, Zheng R, Zhang C,
Wu Y, Zhang X, Li N, Zheng J and Chen D: Radiofrequency
ablation-increased CXCL10 is associated with earlier recurrence of
hepatocellular carcinoma by promoting stemness. Tumour Biol.
37:3697–3704. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Ling CC, Ng KT, Shao Y, Geng W, Xiao JW,
Liu H, Li CX, Liu XB, Ma YY, Yeung WH, et al: Post-transplant
endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling
promotes liver tumor growth. J Hepatol. 60:103–109. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Zhang Y, Zhao W, Li S, Lv M, Yang X, Li M
and Zhang Z: CXCL11 promotes self-renewal and tumorigenicity of
α2δ1+ liver tumor-initiating cells through CXCR3/ERK1/2
signaling. Cancer Lett. 449:163–171. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Li C, Kang D, Sun X, Liu Y, Wang J and Gao
P: The effect of C-X-C motif chemokine 13 on hepatocellular
carcinoma associates with Wnt signaling. Biomed Res Int.
2015:3454132015.PubMed/NCBI
|
|
146
|
Deng L, Chen N, Li Y, Zheng H and Lei Q:
CXCR6/CXCL16 functions as a regulator in metastasis and progression
of cancer. Biochim Biophys Acta. 1806:42–49. 2010.PubMed/NCBI
|
|
147
|
Yuan Y, Liu J, Liu Z, He Y, Zhang Z, Jiang
C and Qian Q: Chemokine CCL3 facilitates the migration of hepatoma
cells by changing the concentration intracellular Ca. Hepatol Res.
40:424–431. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Bai H, Weng Y, Bai S, Jiang Y, Li B, He F,
Zhang R, Yan S, Deng F, Wang J and Shi Q: CCL5 secreted from bone
marrow stromal cells stimulates the migration and invasion of Huh7
hepatocellular carcinoma cells via the PI3K-Akt pathway. Int J
Oncol. 45:333–343. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Liao WC, Yen HR, Liao CK, Tseng TJ, Lan CT
and Liu CH: DSE regulates the malignant characters of
hepatocellular carcinoma cells by modulating CCL5/CCR1 axis. Am J
Cancer Res. 9:347–362. 2019.PubMed/NCBI
|
|
150
|
Li Y, Wu J and Zhang P: CCL15/CCR1 axis is
involved in hepatocellular carcinoma cells migration and invasion.
Tumour Biol. 37:4501–4507. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Lu J, Yang Y, Yu P, Tao H, Lu X, Wang L,
Liu D, Chen Y and Chen C: Bioinformatics analysis and significance
of expression of CC chemokine ligand 23 (CCL23) in hepatocellular
carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 35:903–909.
2019.(In Chinese). PubMed/NCBI
|
|
152
|
Zhuang H, Cao G, Kou C and Liu T:
CCL2/CCR2 axis induces hepatocellular carcinoma invasion and
epithelial-mesenchymal transition in vitro through
activation of the Hedgehog pathway. Oncol Rep. 39:21–30.
2018.PubMed/NCBI
|
|
153
|
Jin L, Liu WR, Tian MX, Jiang XF, Wang H,
Zhou PY, Ding ZB, Peng YF, Dai Z, Qiu SJ, et al: CCL24 contributes
to HCC malignancy via RhoB-VEGFA-VEGFR2 angiogenesis pathway and
indicates poor prognosis. Oncotarget. 8:5135–5148. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Zhu F, Li X, Chen S, Zeng Q, Zhao Y and
Luo F: Tumor-associated macrophage or chemokine ligand CCL17
positively regulates the tumorigenesis of hepatocellular carcinoma.
Med Oncol. 33:172016. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Wiedemann GM, Röhrle N, Makeschin MC,
Fesseler J, Endres S, Mayr D and Anz D: Peritumoural CCL1 and CCL22
expressing cells in hepatocellular carcinomas shape the tumour
immune infiltrate. Pathology. 51:586–592. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Cheng X, Wu H, Jin ZJ, Ma D, Yuen S, Jing
XQ, Shi MM, Shen BY, Peng CH, Zhao R and Qiu WH: Up-regulation of
chemokine receptor CCR4 is associated with Human Hepatocellular
Carcinoma malignant behavior. Sci Rep. 7:123622017. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Mukaida N, Sasaki SI and Baba T: CCL4
signaling in the tumor microenvironment. Adv Exp Med Biol.
1231:23–32. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Luo KQ, Shi YN and Peng JC: The effect of
chemokine CC motif ligand 19 on the proliferation and migration of
hepatocellular carcinoma. Tumour Biol. 35:12575–12581. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Yang L, Chang Y and Cao P: CCR7
preservation via histone deacetylase inhibition promotes
epithelial-mesenchymal transition of hepatocellular carcinoma
cells. Exp Cell Res. 371:231–237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Hou PP, Luo LJ, Chen HZ, Chen QT, Bian XL,
Wu SF, Zhou JX, Zhao WX, Liu JM, Wang XM, et al: Ectosomal PKM2
promotes HCC by inducing macrophage differentiation and remodeling
the tumor microenvironment. Mol Cell. 78:1192–1206.e10. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Xu B, Deng C, Wu X, Ji T, Zhao L, Han Y,
Yang W, Qi Y, Wang Z, Yang Z and Yang Y: CCR9 and CCL25: A review
of their roles in tumor promotion. J Cell Physiol. 235:9121–9132.
2020. View Article : Google Scholar : PubMed/NCBI
|
